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Abstract  
Objective: To evaluate the impact of using a ‘virtual clinic’ on patient experience and cost in 
the care of women with urinary incontinence.  
Materials and Methods: Women, aged > 18 years referred to a urogynaecology unit were 
randomised to either (1) A Standard Clinic or (2) A Virtual Clinic. Both groups completed a 
validated, web-based interactive, patient-reported outome measure (ePAQ-Pelvic Floor), in 
advance of their appointment followed by either a telephone consultation (Virtual Clinic) or 
face-to-face consultation (Standard Care). The primary outcome was the mean ‘short-term 
outcome scale’ score on the Patient Experience Questionnaire (PEQ). Secondary Outcome 
Measures included the other domains of the PEQ (Communications, Emotions and Barriers), 
Client Satisfaction Questionnaire (CSQ), Short-Form 12 (SF-12), personal, societal and NHS 
costs.   
Results: 195 women were randomised: 98 received the intervention and 97 received 
standard care. The primary outcome showed a non-significant difference between the two 
study arms. No significant differences were also observed on the CSQ and SF-12. However, 
the intervention group showed significantly higher PEQ domain scores for Communications, 
Emotions and Barriers (including following adjustment for age and parity). Whilst standard 
care was overall more cost-effective, this was minimal (£38.04). The virtual clinic also 
significantly reduced consultation time (10.94 minutes, compared with a mean duration of 
25.9 minutes respectively) and consultation costs compared to usual care (£31.75 versus 
£72.17 respectively), thus presenting potential cost-savings in out-patient management.  
Conclusions: The virtual clinical had no impact on the short-term dimension of the PEQ and 
overall was not as cost-effective as standard care, due to greater clinic re-attendances in this 
group. In the virtual clinic group, consultation times were briefer, communication experience 
was enhanced and personal costs lower. For medical conditions of a sensitive or intimate 
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nature, a virtual clinic has potential to support patients to communicate with health 
professionals about their condition.   
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Introduction  
One initiative to improve the efficiency and accessibility of outpatient care has been the 
implementation of ‘virtual clinics’. At the heart of a virtual clinic is the use of telemedicine to 
support the assessment, monitoring and management at a distance, away from traditional 
face to face clinic consultation [1]. 
Virtual clinics have been advocated for non-complex cases and have been implemented for 
the management of new [2] and follow-up patients [3-4] and for different specialties in both 
primary [5-6] and secondary care [7-8]. Potential patient benefits include improved 
satisfaction, reduced carbon footprint and reduction in unnecessary appointments and 
journeys to hospital [9].  The format and delivery of a virtual clinic varies widely depending 
upon the technology deployed including telephone [9], online web sessions [6] and Skype [5]. 
ePAQ-PF (electronic Personal Assessment Questionnaire-Pelvic Floor) is a validated, web-
based interactive patient-reported outcome measure which offers in-depth evaluation of a 
woman’s pelvic floor symptoms and their impact on quality of life [10]. Previous research in 
primary and secondary care has established the psychometric properties of the instrument 
[11-13] and the system architecture for which enables patients to securely and anonymously 
complete a detailed, interactive web-based assessment. 
 
Qualitative research involving home completion of ePAQ-PF, suggested positive patient 
experiences. These were particularly in terms of helping women to understand their 
condition, improve communication and prepare them for consultations, [14]. A randomised 
study in the USA observed increased discussion rates relating to intimate conditions in women 
randomised to use ePAQ [15]. It was therefore hypothesized that the assessment provided by 
ePAQ-PF could be used to support telephone consultations in a ‘virtual clinic’. However, such 
a development warranted scrutiny in terms of patient experience and cost [16]. 
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We conducted a randomised controlled trial to evaluate the impact of a virtual clinic (ePAQ-
PF completion) followed by telephone consultation). Our objectives were to compare patient 
experience and cost outcomes in new patients referred to the urogynaecology service who 
utilised the virtual clinic, with women who attended for standard care in the out-patient 
department. 
 
Materials and Methods  
This trial was designed as a randomised, parallel group trial. The study protocol was approved 
by the North Sheffield ethics committee and is registered at www.clinicaltrials.gov (identifier 
NCT02176330). The trial was retrospectively registered because the first participant was 
recruited into the study in June 2008 before the date when prospective registration was 
mandatory. Therefore, it did not become apparent that trial registration was necessary until 
analysing the data and preparing the manuscript for publication. The trial protocol (see S1 File 
Study Protocol) and supporting CONSORT checklist (see S2 File CONSORT Statement) are 
available as supporting information. 
 
Participants 
Participant recruitment and follow-up took place between June 2008 and Oct 2010. All 
women referred to urogynaecology services at Sheffield Teaching Hospitals (STH), aged ≥ 18 
years and able to read and understand English between July 2008 and April 2010 were eligible 
for study entry. Potential participants were identified by review of referral letters received in 
the clinic to which the patient had been referred. Referral letters were screened by senior 
medical staff involved in the study: Women in whom physical examination and urinalysis had 
not been carried out and documented by the referring clinician or GP, or those women in 
whom physical examination was considered essential at initial consultation (e.g. women with 
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prolapse) were excluded from the study. When follow-up arrangements were made, such as 
for outpatient clinic, physiotherapy or urodynamics, it was clearly documented that pelvic 
examination may be required for virtual clinic patients. 
 
Patients considered suitable were then contacted by telephone by the research nurse to 
discuss the study and those interested in participating were then sent a study information 
leaflet and consent form.  
 
Women who did not reply within 1 week were contacted by telephone to assess whether they 
wished to participate in the study. Those women who could not be contacted at this point, or 
who declined study entry were sent a standard outpatient clinic appointment. To prevent 
unwarranted delays, patients who were not contactable by telephone within 48 hours of the 
reciept of the referral letter were excluded from the study and sent a standard outpatient 
clinic appointment, as were patients who expressed no interest in participating in the study.  
 
Control group:  Usual care 
All women randomised to usual care were posted appointment details to attend the 
urogynaecology clinic. 'Usual care' included the option of completing the ePAQ on arrival in 
clinic, immediately prior to the clinical consultation. As is currently standard practice, the 
results of the ePAQ were used to inform and support clinical assessment, however, as the 
ePAQ-PF is completed immediately prior to the clinical consultation, patients were not triaged 
or provided with any additional information on the basis of their questionnaire results. 
 
Intervention Group:  Virtual Clinic 
All women randomised to the virtual clinic were posted information details and a voucher 
letter inviting them to complete the questionnaire on-line. This letter includes details of the 
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web address for ePAQ-online (www.epaq-voucher.co.uk) with information explaining how to 
access and use the website. On completion of the questionnaire, each patient had the option 
of printing her questionnaire report, which included a summary of symptom scores in each 
area (urinary, bowel, vaginal and sexual).  
 
The same clinicians were involved in the outpatient department and therefore a virtual clinic 
and a standard approach was agreed: Confirming patient name, date of birth and expectation 
and willingness to undergo telephone consultation. No answer-machine messages were left if 
patients did not answer the telephone. All virtual clinic patients were offered the opportunity 
to attend in person, including for physical examination, if this was not already deemed 
necessary on conclusion of the telephone consultation. Patients in both standard care and 
telephone consultation were routinely offered a copy of correspondence, including any 
correspondence to their GP. The virtual clinic was based on telephone consultation, which is 
commonly used in patient care and no formal telemedicine training was received 
 
All data were encrypted and anonymised (in line with data protection guidelines) and were 
only personalised to the individual when digitally transferred to the password protected 
server on the N3 network. The clinician used the ePAQ-PF report in conjunction with  the 
patient’s own casenotes and original referral letter to support the subsequent telephone 
consultation (this constituted the Virtual Clinic). The research nurse then arranged their 
telephone consultation. Women in this group who felt unable to complete the questionnaire 
online would use this telephone call with the research nurse to make arrangements to attend 
and complete the questionnaire at the hopsital. 
 
Outcome Measures 
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In order to achieve uniformity of approach (between the Virtual Clinic and the control group) 
valdiated outcome questionnaires; Patient Experience Questionnaire (PEQ [17] and Client 
Satisfaction Questionnaire-8 (CSQ-8) [18] were posted to patients no later than two weeks 
following their first clinic consultation (baseline). Women were asked to complete and return 
these by post. All subjects were also asked to complete the QQ10 [19] (posted no later than 
two weeks after the first clinic consultation). These were analysed to evaluate any differences 
between groups. In addition, a subsample of patients were also asked to complete the Short 
Form-12 (SF-12) [20] at baseline and 6 months afterwards. The reason that only a subsample 
of patients were asked to complete this was because in error, the SF-12 was omitted from the 
questionniares to be completed at baseline. Once this was realised it was sent out. This meant 
there were only those patients included with complete SF-12 data (at baseline and 6 months) 
included in the analysis. 
 
The PEQ 
The PEQ was developed to measure patient experience of a general practice consultation [17]. 
It contains 18 items scored in four domains: 1) Communication, 2) Emotions 3) Short-term 
outcome, 4) Barriers and 5) Auxillary Staff. As this instrument was to be used to assess virtual 
and secondary care consultations, only the first 4 domains (contining 16 items) were 
considered relevant to this study. Domains 1, 3 and 4 are scored from 1 to 5, and the emotion 
scale is scored between 1 to 7. For each of these domains, each patient’s responses were 
summed, and then the mean for that domain calculated. Higher scores represent a positive 
patient experiences relating to communication, emotions, consultation outcome and 
communication barriers. 
  
The CSQ-8  
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The CSQ-8 is a validated instrument which contains 8 items measuring the patient’s 
satisfaction following receiving a service. It is scored by simply summing the individual item 
scores which generates an overall score between 8 to 32. A higher score indicates more 
patient satisfaction [18]. 
 
QQ-10 
The QQ10 (The Questionnaire’s Questionniare 10) is a 10-item instrument specifically 
designed for evaluating patients views on the use of a questionnaire as part of their 
healthcare. The 10 items are scored using a 5-point Likert rating from strongly agree to 
strongly disagree (coded as 0-4) which are then summed to produce two domains relating to 
the value and burden of using the instrument during a healthcare episode. These two domains 
are calculated by summing up scores of the first six questions and of the last four questions 
respectively based upon the patient’s repsonses. The higher the scores for the Value domain 
the more valuable and positive the new questionniare is perceived; and the higher the scores 
for the Burden domain, the more burdensome the new questionniare is perceived by 
participants [19]. 
 
ePAQ-PF 
ePAQ-PF consists of 120 items and 19 scored domains covering the four key dimensions of 
pelvic floor health: Urinary, Bowel, Vaginal and Sexual. Each domain is summed and then 
converted on to a scale from 0 – 100 where 0 indicates perfect health and 100 the worst 
possible health status [11-13]. 
 
The SF-12 
The SF-12 is a standardised, multidimensional, generic measure of health related quality of 
life (HRQOL) [20]. The results were converted into utility values using the SF-6D algorithm 
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(Brazier & Roberts 2004).  These values are anchored on a scale of 0 (death) to 1 (full health) 
which represent individuals preference for a health condition. These values are then 
combined with their timings to calculate an area under the curve, which represents quality 
adjusted life years (QALY) which were employed in the cost utility analyses [21].  The area 
under the curve was estimated using the trapezium rule [22]. 
 
Number and type of referrals  
At 6-month follow-up the number and type of primary and secondary care referrals made on 
behalf of patients in both arms of the study was recorded using a standard proforma.  
 
Cost effectiveness 
The use of ePAQ online prior to clinic appointments and the move away from the traditional 
consultation to a telephone consultation could potentially have significant economic impact, 
whilst also substantially changing patients’ experience of care.  Therefore, an economic 
analysis was undertaken alongside the clinical trial to determine whether the use of ePAQ 
online in combination with telephone consultation was cost-effective when compared with 
standard care. The study estimated the costs of providing assessment and care to six months 
in both arms of the study, and cost-effectiveness by an incremental cost per QALY. Analyses 
were performed from two perspectives; (1) the cost to the NHS and (2) a broader societal cost 
that included patient expenditure and lost productivity. Due to the six month timeframe, no 
discounting of costs of effects was indicated. An economic evaluation was undertaken 
alongside the trial in line with good practice guidelines [23] and reported according to the 
Consolidated Health Economic Evaluations Reporting Standards (CHEERS) statement [24].  
 
Resource use 
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Resource use data were collected at two time points: (1) Initial consultation and (2) Six month 
follow-up. A micro-costing study was undertaken on a sub-set of patients to derive costs for 
initial ePAQ completion and consultation; for these patients their consultation was timed and 
costs for staff time, computers, software and overheads were applied. Six months following 
study recruitment, patients were posted a questionnaire asking for resources used since their 
consultation. Resource use data included personal expenditure relating  to (1) Bladder, bowel 
or vaginal problems; (2) Time off work; (3) Time away from usual activities; (4) Visits to the 
general practitioner, nurse or other health professionals, and (5) Inpatient and outpatient 
visits. The proforma also recorded details of prescribed medication, however, most patients 
included this within personal expenditure and due to the inconsistent reporting of 
prescription data, these costs were excluded from the economic analysis.   
UK unit costs were applied to resource use estimates for patients in each study arm. All costs 
were inflated to 2011 United Kingdon (UK) prices using the pay and prices index [25] and 
value-added tax (VAT) was excluded in line with NICE guidance [26]. Staff time was costed 
using the Unit Costs of Health and Social Care publication and included overhead costs [25]. 
Costs of surgical procedures were estimated using a per-elective inpatient episode cost based 
on the National Schedule of Reference Costs [27]. 
Statistical Power 
The primary outcome for the purpose of sample size determination was the mean outcome 
scale sore on the PEQ completed after first clinical consultation.  Steine et al [17] reported a 
mean score of 2.9 (SD 1.0) for the outcome scale of the PEQ and mean score of 5.0 (SD 1.2) 
for the emotional scale.  If we assume an SD of 1.0 for the outcome scale and that a mean 
difference of 0.5 or more points between the intervention and control groups is of both 
clinically and practical importance, then to achieve 90% power for demonstrating this mean 
difference as being statistically significant at the 1% (two sided) level, this study would require 
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121 women per group (242 in total).  Assuming that 20% of patients would not return 
completed questionnaires, the study aimed to recruit 304 patients (152 per group). 
 
Randomisation 
Randomisation occured on receipt of signed consent forms. Allocation was through stratified 
block randomisation. A senior statistician within ScHARR generated a randomisation schedule 
for these strata, using STATA software. This was held remotely by another research nurse, 
who was not directly involved in recruiting patients to this study. By referring to the list, she 
allocated patients to either the intervention group (ePAQ + telephone consultation) or the 
control group (standard care) and placed these randomised group numbers in a sealed 
envelopes. The randomised allocation enveloped were then passed on to the research nurse 
who opened them sequentially for each patient who consented to participate in the study. It 
was not possible to blind the clinicians or patients to the intervention. Those analysing the 
main study and cost-effectiveness outcomes were blinded until the point of data analysis. 
 
Statistics and Data Analysis:  
Statistical analysis was conducted on an ‘intention-to-treat’ basis with the principal analysis 
directed to difference between post-consultation scores on the PEQ.  A p-value ≤0.05 was 
regarded as statistically significant.  As the study was a two-parallel group RCT, the study was 
reported according to the CONSORT guideline [28]. 
 
For the primary analysis, post-consultation PEQ scores were compared between the two arms 
(intervention and standard care), with analyses adjusted and unadjusted for covariates.  The 
unadjusted analysis used a 2-independent samples t-test to compare mean post consultation 
PEQ scores between the two groups.  A ninety-five percent confidence interval (CI) for the 
mean difference in post consultation scores between the two treatment groups was reported.  
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The adjusted analysis used an analysis of covariance (ANCOVA) model with post consultation 
PEQ scores as the outcome and, age as a covariate.  A 95% CI for the treatment group 
regression coefficient was reported.   
 
Analysis of the post-consultation satisfaction scores followed the same format as the primary 
outcome. Due to the skewed distribution of the number of referrals the distributions were 
compared between the two arms (intervention and usual care) using Mann-Whitney U tests.  
The difference in proportion of patient referred and a ninety-five percent CI for the difference 
in proportion between the two treatment groups was reported.  Multiple imputation using a 
regression model with age, BMI and parity was carried out on the primary outcome but found 
that it had no influence on the conclusions of the hypothesis tests. 
 
Results 
A total of 515 referral letters were received but after screening by the clinical team for 
eligibility 434 women were telephoned about the study. Following the conversation with the 
research nurse, 293 women were sent the study information. The main reasons for declining 
participation included insufficient time to take part (e.g. patients had already been admitted 
to hospital), decided a different treatment pathway e.g. (private consultation), inappropriate 
(for reasons such as pregnancy, language barriers, learning difficulties, family circumstances, 
or other health problems such as cancer and deafness, and unsure if keeping the 
appointment). One hundred and ninety-five women returned the consent form and were 
randomised into the study. Ninety-eight women received the intervention and 97 received 
standard care (Fig 1).  
 
 
Fig 1: Participant progression through the trial – CONSORT flow chart 
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However, six women in the intervention arm withdrew consent. Table 1 shows the baseline 
characteristics of the women who were randomised to the two groups.  The mean age was 
50.6 years in the control group (SD: 10.5; range 24.7-71.5 years) and 51.5 years in the 
intervention group (SD: 11.3; range 28.8-75.5 years). A comparison of baseline 
characteristics between those included in the primary analysis and those excluded 
from the primary analysis showed no real differences between the groups (S1 Table 
Baseline characteristics of those patients analysed vs. those not analysed by 
treatment group). 
 
 
Table 1: Baseline characteristics of all randomised patients by treatment group. 
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 Control (n = 97) Intervention (n = 98)  
n Mean SD Range n Mean SD Range  
Age (years)  95 50.6 10.5 24.7 – 
71.5 
91 51.5 11.3 28.8 – 
75.5 
 
Height (m)  93 1.63 0.07 1.47 – 
1.80 
91 1.63 0.07 1.50 – 
1.78 
 
Weight (kg)  93 70.4 13.7 45.5 – 
122.0 
87 71.9 13.3 48.0 – 
113.0 
 
BMI  92 26.6 5.3 19.4 – 
49.1 
87 27.2 4.9 19.7 0 
45.8 
 
Parity  97 2  0 – 5 91 2  0 – 6  
Nationality: American 0 (0%)   1 (1%)    
British 95 (98%)   88 (97%)    
European 1 (1%)   1 (1%)    
Irish 1 (1%)   1 (1%)    
Ethnic 
Origin: 
White 
British 
95 (98%)   86 (95%)    
White Irish 1 (1%)   1 (1%)    
White 
Other 
0 (0%)   3 (3%)    
Mixed Race 1 (1%)   1 (1%)    
Education 
Level: 
None 17 (17%)   14 (16%)    
Junior 26 (27%)   30 (33%)    
Senior 27 (28%)   21 (23%)    
University 27 (28%)   25 (28%)    
Marital 
Status: 
Married 71 (73%)   64 (70%)    
Cohabiting 8 (8%)   8 (9%)    
Single 2 (2%)   4 (4%)    
Widowed 5 (5%)   3 (3%)    
Divorced 8 (8%)   10 (11%)    
Separated 3 (3%)   1 (1%)    
Civil 
Partnership 
0 (0%)   1 (1%)    
 
 
 
There was no significant difference in the symptom profiles (as measured by ePAQ) in the two 
groups. The most prevalent conditions were stress incontinence and overactive bladder, and 
approximately 1/3 reporting sexual dysfunction. Women who were felt to need examination 
at their first assessment were excluded from the study, which is reflected in the low incidence 
of symptomatic and bothersome prolapse, reported by the women (Table 2).  
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Table 2: ePAQ domains scores for the study sample. 
 ePAQ-PF Domains 
N Mean Domain 
Scores – Virtual 
Clinic* 
N Mean Domain 
Scores – Standard 
Care* 
 Urinary     
 Pain 88 11.8 89 11.5 
 Voiding 89 8.9 91 11.7 
 OAB 87 34.5 91 31.3 
 Stress 88 43.1 92 45.7 
 QoL 87 58.3   
 Bowel     
 IBS 88 26.5 92 25.4 
 Constipation 86 22.0 91 18.4 
 Evac 84 17.8 92 15.9 
 Continence 86 13.1 91 13.1 
 QoL 83 16.3   
  Vaginal     
 Pain & sensation 86 20.7 91 29.6 
 Capacity 82 4.7 86 5.3 
 Prolapse 87 13.4 89 18.4 
  QoL 83 15.2 89 15.4 
  Sex     
  Urinary & Sex 75 26.3 81 29.0 
  Bowel & Sex 69 9.6 76 7.2 
  Vagina & Sex 74 23.7 79 27.0 
 Dyspareunia 74 21.7 79 21.2 
  Overall sex life 79 35.2 79 36.4 
 
*NB: 0 = Perfect health, whereas 100 = worst health 
  
 
The intervention group had a statistically significant difference in subsequent referrals to a 
general practitioner.  The difference in proportions (and 95% CI) between treatment groups 
was 24.5% (6.8 to 42.1), p=0.008 and the Mann-Whitney U test showed an overall difference 
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in distribution (p=0.015).  The differences in subsequent referrals to practice nurse and 
outpatient between treatment groups were not statistically significant (Table 3).
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Table 3: Number of referrals over 6 months by treatment group 1 
 2 
 3 
 Treatment Group  
Control Intervention 
N Proportion1 
 
Total 
Referrals2 
   
Median Range N Proportion1 
 
Total 
Referrals2 
 
Median Range Difference in 
Proportion3 
(95% CI) 
P-Value4 P-Value5 
General 
Practitioner 
55 23.6% 33 0 0 - 10 52 48.1% 43 0 0 - 5 24.5% 
(6.8, 42.1) 
0.008 0.015 
Practice 
Nurse 
55 10.9% 10 0 0 – 3 50 10.0% 7 0 0 - 2 -0.9% 
(-12.6, 10.8) 
0.879 0.856 
Outpatient* 
 
55 63.6% 80 1 0 - 5 52 65.4% 76 1 0 - 9 1.8% 
(-16.4, 19.9) 
0.850 0.818 
1 Proportion of patients having at least one referral 4 
2Total number of referrals 5 
3A positive difference in proportion indicates the intervention has a higher proportion of referrals 6 
4P-Value from a Chi-Square test for difference in proportions 7 
5P-Value from a Mann-Whitney U Test comparing the distribution of referrals  8 
*Non-surgical hospital outpatient9 
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Results: Patient Experience 10 
 11 
The primary outcome was the short term outcome score of the PEQ post consultation. This 12 
includes 4 questions relating to knowledge and understanding of a health problem 13 
comprising: 1. Do you know what to do to reduce your health problems? (or how to prevent 14 
further health problems?), 2. Do you know what to expect from now on?, 3. Will you be able 15 
to handle your health problems differently? and,  4. Will it lead to fewer health problems? (or 16 
help you to prevent such problems? This was available for 137 women (i.e. 70% of the original 17 
cohort) that could be analysed.  There was no reliable evidence of a statistically significant 18 
difference in the short-term dimension between the control and intervention groups (Table 19 
4).  20 
 21 
Table 4: Unadjusted and adjusted differences in mean Patient Experience Questionnaire 22 
scores post consultation by treatment groups 23 
 24 
 Control  Intervention Unadjusted2 Adjusted3 
N Mean SD N Mean SD 
Mean 
Diff 
95% CI 
P-
Value 
Mean 
Diff 
95% CI 
P-
Value 
PEQ dimension1 Lower Upper Lower Upper 
Short-term 
outcome** 
69 2.9 1.1 68 2.9 1.2 -0.04 -0.4 0.3 0.843 -0.03 -0.4 0.4 0.887 
Communications 68 3.8 0.8 68 4.2 0.6 0.4 0.2 0.6 0.001 0.4 0.2 0.7 0.001 
Emotions 66 4.6 1.3 64 5.4 1.2 0.7 0.2 1.1 0.001 0.7 0.3 1.1 0.002 
Barriers 68 4.0 0.6 67 4.4 0.6 0.3 0.1 0.5 0.002 0.3 0.1 0.5 0.003 
 25 
1The PEQ dimensions are scored on a 1-5 scale with the exception of emotions which is 1-7. A 26 
high score represents a good communication experience, positive emotions, positive 27 
consultation outcome and a lack of communication barriers. 28 
2P-value from independent samples t-test 29 
3Adjusted mean difference calculated from a linear regression model with PEQ dimension 30 
score as the outcome and age, parity and treatment group as covariates. A positive mean 31 
difference indicates that the intervention group has the better score. 32 
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**This domain asks 4 questions  33 
1. Do you know what to do to reduce your health problems? (or how to prevent further health 34 
problems?) 35 
2. Do you know what to expect from now on? 36 
3. Will you be able to handle your health problems differently? 37 
4. Will it lead to fewer health problems? (or help you to prevent such problems?). 38 
 39 
 40 
 41 
The unadjusted mean difference (and 95% CI) between treatment groups for the short term 42 
outcome was -0.1 (-0.4 to 0.3), p = 0.84.  There was a statistically significant difference 43 
between the control and intervention groups for the other three dimensions of the PEQ 44 
(communications, emotions and barriers).  The mean difference (and 95% CI) between 45 
treatment groups was 0.4 (0.2 to 0.6), p = 0.001 for the communications dimension, 0.7 (0.2 46 
to 1.1), p = 0.001 for the emotions dimension and, 0.3 (0.1 to 0.5), p = 0.002 for the barriers 47 
dimension. These results remained after adjusting for the covariates of age and parity.   48 
 49 
The age and parity adjusted mean difference (and 95% CI) between groups for the short term 50 
outcome was not significant -0.03 (-0.4 to 0.4), p = 0.887.  There was a statistically significant 51 
difference between the control and intervention groups for the other three dimensions of the 52 
PEQ (communications, emotions and barriers).  The mean difference (and 95% CI) between 53 
treatment groups is 0.4 (0.2 to 0.7), p = 0.001 for the communications dimension, 0.7 (0.3 to 54 
1.1), p = 0.002 for the emotions dimension and, 0.3 (0.1 to 0.5), p = 0.003 for the barriers 55 
dimension (S1 Fig Mean difference between groups and 95% CI for post consultation PEQ 56 
scores). 57 
 58 
Results: Cost-Utility analysis 59 
The primary cost-effectiveness analysis was completed on patients with complete cost and 60 
outcome data (Control group N = 30; Intervention Group N = 27).  Unit costs (S2 Table Unit 61 
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Costs) were applied to resource use estimates (S3 Table Resource Use Within 6 Months Follow 62 
Up) for each treatment arm. Estimates of mean direct and indirect costs by intervention group 63 
can be seen in Table 5.   64 
Table 5: Mean Costs per Patient by treatment group (complete case analysis). 65 
Resource Cost per patient 
Group 1 
(Intervention) (£) 
N = 27 
Cost per patient 
Group 2 (control) 
(£) 
N = 30 
Mean 
Difference 
(£) 
95% 
Confidence 
Interval 
Lower 
95% 
Confidence 
Interval 
Upper 
P-value 
Cost of consultations        
Consultation cost1  29.35 69.52 -40.17 - - - 
Cost of software 2.40 2.40 0 - - - 
Cost of computer N/A 0.25 -.25 - - - 
Total consultation 
costs per patient 
31.75 72.17 40.42 - - - 
Direct costs during 6 
month follow-up 
      
GP Visits 41.22 (49.49) 35.33 (65.78) 5.89 -25.29 37.06 .654 
Practice nurse 0.94 (3.40)  2.13 (5.88) -1.18 -3.77 1.41 .063 
Outpatient visits 250.67 (316.09) 188.00 (246.547) 62.67  -87.02 212.36 .405 
Cost of surgical 
procedures2 
330.44 (707.375) 285.63 (784.36) 44.88 -353.35 442.97 .822 
Other professionals -  -  -  -  -  -  
Physiotherapist - 5.04 (12.59) - 4.99 (15.76) .05 -7.58 7.68 .989 
Specialist nurse 
(including stoma 
nurse, incontinence 
nurse, gynaecology) 
4.52 (18.35) 2.03 (11.14) 2.49 -5.48 10.45 .534 
Consultant (f2f) 7.94 (24.44) 14.29 (37.06) -6.35 -23.22 10.51 .454 
Total direct costs  640.77 (844.40) 532.41 (867.09) 108.37 -346.93 563.67 .635 
Indirect costs during 6 
month follow-up 
      
Personal expenditure 
in 6 month follow-up 
period (£) 
24.07 (31.05) 16.17 (20.97) 7.9 -6.04 21.84 .261 
Loss of productivity 443.26 (1573.15) 481.07 (1475.01) -37.81 -847.04 771.42 .926 
Total indirect costs 467.33 (1569.42) 497.24 (1479.79) -29.91 -839.47 779.66 .946 
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 66 
1Consultation cost includes consultant time and overheads.  67 
2Healthcare Resource Group (HRG) codes included were validated by a clinician 68 
 69 
 70 
 71 
 72 
Consultation costs for the intervention group were less than half the costs of the control group 73 
(£31.75 versus £72.17), due primarily to the duration of the consultation and associated 74 
labour costs. The mean duration of the telephone consultation was 10.94 minutes, compared 75 
with a mean duration of 25.9 minutes for patients attending a face-to-face consultation.  76 
 77 
Direct costs incurred during the 6 month follow-up period differed between treatment arms, 78 
with patients in the intervention group incurring non-significantly greater direct costs in 79 
comparison with the control group. This was driven primarily by the difference in costs 80 
associated with gynaecology outpatient attendances between arms, with those in the 81 
intervention group incurring costs of £62.67 greater than those in the control group.  82 
 83 
Personal expenditure accrued at 6 month follow-up was higher in the intervention group 84 
However, lower costs associated with loss of productivity for the intervention group resulted 85 
in lower total (per-patient) indirect costs.  The mean total cost per patient was estimated to 86 
be £1,139.86 for patients receiving the intervention and £1101.82 for the control group. This 87 
resulted in a non-significant mean differential cost of intervention versus control of £38.04. 88 
 89 
Mean utility estimates by intervention are shown in Table 6. Within the intervention group, 90 
mean utility estimates reduced slightly from baseline to 6 months, whilst the equivalent 91 
Total costs per 
patient 
1,139.86 
(2182.24) 
1101.82 
(2172.44) 
38.04 -1119.34 1196.03 .948 
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estimates for Group 2 showed a slight increase. These estimates resulted in a non-significant  92 
QALY loss for patients in the intervention group relative to standard care of 0.0095 (p=0.40).  93 
 94 
 95 
 96 
 97 
 98 
 99 
Table 6: Mean utility per patient by intervention group (complete case analysis)  100 
 101 
Item Group 1 
(Intervention)  
(N=27) 
Group 2  
(Control) 
(N = 30) 
 95% CI of difference  
 Mean (SD) Mean (SD) Difference (SE) Lower upper Significance 
SF-6D 
baseline 
.64 (0.090) .62 (.081) .026 (.024) -.022 .07441 .287 
SF-6D 6 
months 
.63 (.082) .62 (.091) .00698 (.023) -.039 .05314 .763 
Change 
in SF-6D 
-.0152 (.073) .0038(.094) -.01899 (.02245) -.06397 .02600 .401 
QALYs 
gained 
-.0076 (.037)  .0019 (.047)   -.0095 (.1122) -.3199 .01300 .401 
 102 
 103 
 104 
The cost-effectiveness acceptability curve (CEAC) for the complete case analysis (S2 Fig The 105 
Cost Effectiveness Acceptability Curve) indicates that under the commonly used funding 106 
threshold of £20k per QALY gained, the probability that the intervention is cost-effective is 107 
approximately 35%. After accounting for missing data through the use of multiple imputation 108 
the probability of cost-effectiveness increases to approximately 48% for the same threshold.  109 
 110 
Discussion 111 
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This randomised clinical trial investigated the effect of a ‘virtual clinic’ in urogynaecology on 112 
patient experience and cost. In terms of patient experience, the trial did not find any 113 
difference in the primary outcome (short term outcome dimension of the PEQ) between 114 
intervention and standard care, nor did the virtual clinic appear to affect general quality of 115 
life, satisfaction or women’s perceptions of using an online questionnaire system during their 116 
clinical episode. There was a statistically significant difference between the two study arms 117 
for the three other dimensions of the PEQ (communications, emotions and barriers). This 118 
finding suggests that for medical conditions of a sensitive and intimate nature, a positive 119 
element of implementing and using a virtual clinic includes the potential to better support 120 
patients to communicate health concerns, avoiding the embarrassment associated with 121 
describing and discussing intimate symptoms during a face to face consultation.    122 
 123 
In clinical practice, patient assessment is central to diagnosis and management with a view to 124 
improving quality of life. It is well recognised that clinical interview data may be unreliable, 125 
being based on clinicians’ rather than patients’ views of their condition [29]. This is particulary 126 
relevant for sensitive areas such as urogynaecology, where computer or web-based formats 127 
have been found to result in greater disclosure [30]. The major advantage of administering 128 
PROMs electronically, compared with paper questionnaires, relate to the practicalities of 129 
clinical data capture; which can be superior in terms of efficiency and response rate and cost 130 
analysis has shown potential economic advantages [31-34]. It seems appropriate therefore, 131 
to seek ways of enhancing clinical assessment through well-designed and tested ePROMs in 132 
order to improve the quality of care and reliably measure outcome.  133 
 134 
Whilst a comparison of a paper ePAQ with it’s electronic counterpart has not been carried 135 
out, our previous qualitative work has found the web-based version of value to patients, 136 
especially in terms of enhanced communication and preparedness for clinical 137 
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consultation [14]. Our findings also suggest that a virtual clinic is a way of deploying web- 138 
based patient-reported outcome measures to support clinical consultations with potential 139 
benefits to patients in terms of experience and expense, although further evaluation in 140 
different clinical contexts is needed. 141 
 142 
Overall, the standard care pathway was more cost effective, (52% chance that it was cost- 143 
effective based on the imputed analysis) which appeared to be the consequence of 144 
subsequent clinic attendance by a higher proportion of patients in this group. However, the 145 
trial found a significant difference between the duration of consultations (which were 146 
approximately 50% shorter in the intervention group) and associated consultation costs. The 147 
cost-effectiveness outcomes in the present study follow the same trend as shown in other 148 
studies. For example, Pinnock et al [35] found that telephone consultations for routine asthma 149 
reviews were less expensive than face-to-face consultations (£10.03 versus £12.74, mean 150 
difference £3.71; 95%CI = 1.92 to 3.50, P<0.001). Conversely, Beaver et al [3] performed an 151 
economic evaluation alongside a clinical trial, comparing hospital attendance with telephone 152 
follow-up after treatment for breast cancer and observed that patients receiving telephone 153 
follow-up had longer consultations, which was one reason for the resulting higher costs.  154 
 155 
A strength of the current study was that it adopted a randomised trial design and thus was of 156 
high methodological quality and reduced risk of bias [36]. The study also recruited women 157 
attending routine clinical practice. However, due to the limited time of the grant award, only 158 
195 of the target 304 participants were recruited and we were unable to extend recruitment, 159 
which is a limitation of the study. The lack of power also means that we cannot be certain 160 
there is no difference in the primary outcome, and the results should be treated with caution. 161 
Whilst recruitment ended in 2010 and thus the data is quite old now, we consider the results 162 
and our experiences of delivering a virtual clinic to still be of interest. Virtual clinics and the 163 
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implementation of web-based technology is still very much a developing area in healthcare 164 
and there have been minimal changes to NHS tariffs and associated costs relevant to this study 165 
during the time since data collection ended.  166 
 167 
The cost-effectiveness analysis suggests that the intervention is unlikely to be cost-effective 168 
at the £20,000 threshold.  However, there are two problems with this simple interpretation.  169 
Firstly, as highlighted above, the inclusion of costs unrelated to the consultation introduces 170 
uncertainty and potential bias; the briefer consultations and lower unit costs, with associated 171 
patient satisfaction (communication) ratings, may be of value when considering different care 172 
pathways, particularly where further attendance, examination or investiagtions are unlikely 173 
to be required (e.g. surgical follow up). Secondly, whilst the SF-6D is considered the most 174 
appropriate generic utility measure for this type of intervention, it may not be reasonable to 175 
expect it to detect subtle effects of the intervention.  Whilst patient experience and 176 
convenience could plausibly impact on wellbeing in the period immediately following an 177 
encounter with health services, it is unlikely that the SF6D woud detect this at six months.  The 178 
cost-effectiveness acceptability curves are relatively flat, which demonstrate large amounts 179 
of uncertainty in both the costs and QALYs, and as such, are compatible with the view that the 180 
use of the SF6D is of little relevance in this context. 181 
 182 
In light of these issues, it may be appropriate to take a more pragmatic approach that focuses 183 
on a broader range of benefits.  This approach is termed a cost-consequences analysis [37] 184 
and is adopted in cases such as this when a simple incremental cost-effectiveness ratio (ICER) 185 
is not thought to capture all the relevant programme outcomes. If we adopt a more flexible 186 
stance that takes into account the wider effects of the intervention, we can see the potential 187 
value of this technology in reducing consultation costs and improving the communication 188 
experience of the patient.   189 
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 190 
The impact of treatment processes on well-being needs further consideration. Whilst several 191 
studies have identified so-called ‘process utility’, the methods by which this can be valued and 192 
incorporated into cost-effectiveness analysis is an under-researched area [38]. In situations 193 
where better patient experience is delivered at higher cost, decision makers need a way to 194 
guage whether or not the service change is worthwhile, given the opportunity cost of a 195 
compensatory service reduction elsewhere.  Methods that can measure and capture process 196 
utility in a way that can be usefully included in cost-effectiveness analyses warrants further 197 
exploration and development. 198 
 199 
Conclusions 200 
The virtual clinical had no impact on the short-term dimension of the PEQ and overall was not 201 
as cost-effective as standard care, which was attributed to subsequent clinic attendance by a 202 
higher proportion of patients in this group. However, for women referred to secondary care 203 
with urinary incontinence, the virtual clinic was associated with briefer consultation times, 204 
lower personal costs and enhanced communication. For medical conditions of a sensitive and 205 
intimate nature, a virtual clinic has potential to better support patients to communicate with 206 
health professionals about their condition. This approach does not appear to affect general 207 
quality of life, satisfaction or perceptions of using an online questionnaire system during their 208 
clinical episode.  209 
 210 
To ascertain whether a virtual clinic can translate into genuine cost savings, future research is 211 
recommended in patient groups in whom subsequent additional clinic re-attendance 212 
(including additional GP attendance), is unlikely to be required, for example surgical follow- 213 
up. 214 
 215 
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